|
kEUR |
2024 |
2023 |
|
|
|
|
|
Revenue at constant currency rates 1 |
336,653 |
332,192 |
|
Impact from changes in exchange rates compared to prior period |
139 |
-11,820 |
|
Revenue reported (IFRS) |
336,792 |
320,372 |
1 Revenue translated into the presentation currency, EUR, using the weighted average EUR currency exchange rate from the prior period.
|
|
2024 vs 2023 |
2023 vs 2022 |
|
|
|
|
|
Change in revenue reported (IFRS) (%) |
5.1% |
14.0% |
|
Change in revenue at constant currency rates (%) 1 |
5.1% |
18.2% |
1 The change is calculated as: (Current period's revenue at constant currencies) / (Prior period's revenue reported (IFRS)) - 1.
|
kEUR |
H1 2024 |
H2 2024 |
FY 2024 |
H1 2023 |
H2 2023 |
FY 2023 |
|
|
|
|
|
|
|
|
|
Revenue not associated with the coronavirus pandemic |
135,043 |
201,749 |
336,792 |
130,327 |
184,221 |
314,548 |
|
Revenue associated with the coronavirus pandemic |
– |
– |
– |
1,507 |
4,317 |
5,824 |
|
Revenue reported (IFRS) |
135,043 |
201,749 |
336,792 |
131,834 |
188,538 |
320,372 |
|
kEUR |
2024 |
2021 |
|
|
|
|
|
Commercial |
218,644 |
115,120 |
|
Contract Manufacturing |
174,175 |
89,600 |
|
Generics & Cosmetics |
44,469 |
25,520 |
|
Development |
118,148 |
167,006 |
|
Custom Projects, excl. revenue associated with the coronavirus pandemic |
118,148 |
103,812 |
|
Revenue associated with the coronavirus pandemic |
– |
63,194 |
|
Revenue reported (IFRS) |
336,792 |
282,126 |
1 According to Note 3 in the consolidated financial statements, the Group generates revenue that can be divided into three business areas. However, to discuss business drivers more concisely, revenue of the business areas Contract Manufacturing and Generics & Cosmetics has been combined into “Commercial revenue” in the table above, while revenue in the business area Custom Projects is labelled “Development revenue”.
|
kEUR |
2024 |
2021 |
|
|
|
|
|
Metabolic |
133,363 |
62,219 |
|
Oncologic |
56,245 |
40,189 |
|
Other, excl. revenue associated with the coronavirus pandemic |
147,184 |
116,524 |
|
Revenue associated with the coronavirus pandemic |
– |
63,194 |
|
Revenue reported (IFRS) |
336,792 |
282,126 |
|
kEUR |
2024 |
2021 |
|
|
|
|
|
Large pharma |
205,504 |
119,429 |
|
Biotech, excl. revenue associated with the coronavirus pandemic |
91,968 |
66,710 |
|
Revenue associated with the coronavirus pandemic |
– |
63,194 |
|
Other |
39,320 |
32,793 |
|
Revenue reported (IFRS) |
336,792 |
282,126 |
|
kEUR |
2024 |
2023 |
|
|
|
|
|
Operating result (EBIT) |
-7,364 |
-36,468 |
|
Depreciation, amortization and impairment charges (if any) |
32,714 |
30,469 |
|
EBITDA |
25,350 |
-5,999 |
|
kEUR |
2024 |
2023 |
|
|
|
|
|
Operating result (EBIT) |
-7,364 |
-36,468 |
|
Average 1 Net operating assets: |
|
|
|
Total non-current assets (average) |
395,420 |
343,349 |
|
Total current assets (average) |
327,412 |
289,086 |
|
Cash and cash equivalents (average) |
-81,992 |
-66,617 |
|
Total current liabilities (average) |
-185,477 |
-136,251 |
|
Average 1 Net operating assets |
455,363 |
429,567 |
|
Return on net operating assets (RONOA) |
-1.6% |
-8.5% |
1 The average amounts are calculated as: (Current period's figures + prior period's figures) / 2.
|
kEUR |
2024 |
2023 |
|
|
|
|
|
Net cash flows from operating activities |
89,399 |
36,485 |
|
Acquisition of intangible assets |
-1,217 |
-3,836 |
|
Acquisition of property, plant and equipment |
-85,751 |
-52,897 |
|
Free Cash Flow |
2,431 |
-20,248 |
|
kEUR |
2024 |
2023 |
|
|
|
|
|
Cash and cash equivalents |
68,277 |
95,706 |
|
Interest-bearing liabilities (Total financial debt): |
|
|
|
Interest-bearing loans and borrowings (Non-current) |
-39,420 |
-49,087 |
|
Lease liabilities (Non-current) |
-18,982 |
-18,869 |
|
Other financial liabilities (Non-current) |
-9,508 |
-9,893 |
|
Interest-bearing loans and borrowings (Current) |
-30,642 |
-41,253 |
|
Lease liabilities (Current) |
-5,073 |
-4,453 |
|
Other financial liabilities (Current) |
-1,266 |
-1,227 |
|
Interest-bearing liabilities (Total financial debt) |
-104,891 |
-124,782 |
|
Net Cash / (debt) |
-36,614 |
-29,076 |
|
kEUR |
2024 |
2023 |
|
|
|
|
|
Property, plant and equipment assets capitalized |
86,777 |
51,993 |
|
Intangible assets capitalized |
1,062 |
2,897 |
|
Capital expenditures (Capex) |
87,839 |
54,890 |